Cannabinoid Formulation for Opioid-Sparing Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management options, particularly opioid-based medications, often come with undesirable side effects such as addiction and constipation, necessitating the development of alternative formulations that can provide effective pain relief without the need for opioids.
Innovation Solution
A cannabinoid formulation comprising tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) in a 1:1:1 ratio, administered alone or in combination with other formulations, to provide opioid-sparing pain management for various types of pain, including cancer, injury, and neuropathic pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid-based medications are used for pain management, then effective pain relief is achieved, but addiction and constipation occur
Solution Approach 1:
The patent changes the chemical composition parameters by using a specific ratio of cannabinoids (THC:CBC:CBD of 1:1:1 or 5:5:5) to achieve effective pain relief while eliminating the harmful side effects associated with opioid medications. This parameter change in the active ingredients resolves the contradiction between effectiveness and harmful effects.
Solution Approach 2:
The patent employs a composite formulation combining three different cannabinoids (THC, CBC, and CBD) in specific ratios. This composite approach leverages the synergistic effects of multiple compounds to provide effective analgesia while avoiding the addiction and constipation problems inherent in single-component opioid medications.
2Object-generated harmful factors
If alternative pain management options are developed, then addiction risk is reduced, but pain relief effectiveness may be compromised
Solution Approach 1:
The patent merges three distinct cannabinoids with different pharmacological profiles into a single formulation. THC provides analgesic effects, CBD contributes to pain relief without psychoactivity, and CBC adds complementary analgesic properties. This combination achieves effective pain relief comparable to opioids while maintaining a low addiction risk profile.
Solution Approach 2:
The patent optimizes the concentration parameters of each cannabinoid component to ensure adequate pain relief. By carefully adjusting the ratios and amounts of THC, CBC, and CBD, the formulation achieves therapeutic effectiveness that matches or exceeds opioid performance while avoiding their harmful side effects.
3Object-generated harmful factors
If opioid dosage is reduced, then addiction risk decreases, but pain management effectiveness may be insufficient
Solution Approach 1:
The cannabinoid formulation acts as an intermediary substance that can replace opioids in pain management. By introducing this alternative mechanism of action through cannabinoid receptor interaction, the system achieves effective pain relief without requiring opioid receptors, thereby reducing addiction risk while maintaining or improving pain management effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively reduces pain sensitivity and improves mobility, offering a safer alternative to opioids by potentially reducing opioid use or eliminating the need for them altogether, thereby addressing the limitations of existing pain management options.
Implementation Method 1
Cannabinoids are a group of structurally similar compounds isolated from cannabis plants, which activate cannabinoid receptors and ion channels in cells
Implementation Method 2
Cannabinoids are a group of structurally similar compounds isolated from cannabis plants, which activate cannabinoid receptors and ion channels in cells
Implementation Method 3
CBD is regarded as having an effect on 5HT1A receptor-mediated neurotransmission
Implementation Method 4
CBD is regarded as having an effect on 5HT1A receptor-mediated neurotransmission, as well as on anandamide metabolism
Implementation Method 5
Δ9-THC exerts partial agonistic activity on CB1 and CB2 receptors with high binding affinity with CB1 receptor leading to its psychoactive activity
Implementation Method 6
CBC has also shown anti-inflammatory effects
Implementation Method 7
CBC has also shown anti-inflammatory effects
Data Source
AI summary
A method of opioid sparing in a subject in need of pain management is described. The method comprises administering an effective amount of a formulation consisting of tetrahydrocannabinol (THC), cannabichromene (CBC), cannabidiol (CBD) and excipients; wherein the weight % ratio of THC:CBC:CBD is 1:1:1. In one embodiment, the 1:1:1 formulation can be used in conjunction with an additional formulation containing CBC:CBD at 1:5 to 5:5 weight %, for use at certain times of day when psychoactive effects of THC are not desired. Then at other times of day, the formulation comprising THC, CBC, and CBD can be used, for example at evening or bedtime. In some embodiments, the subject is one who has previously been administered an opioid medication for pain management, and the administration of the formulation is concomitant with a reduction in the administration of the opioid medication.